computational disease models

CytoReason, a leading developer of computational disease models for efficient drug discovery and development, announced the signing of a commercial…

CytoReason, a leading developer of computational disease models for efficient drug discovery and development, announced the extension of its…

Using its proprietary computational disease models, CytoReason will help Merck understand the drug’s mechanism of action, identify patient populations…

CytoReason, an AI company developing computational disease models for discovery and clinical drug development, and Summit Pharmaceuticals…